Adaptimmune appoints two to board
This article was originally published in Scrip
Executive Summary
Adaptimmune, a T-cell therapy company developing treatments for cancer and infectious diseases, has appointed Dr Jonathan Knowles to its board as a non-executive director, and Dr Helen Tayton-Martin joins the board as an executive director. Dr Knowles was formerly president of group research and a member of the executive committee at Roche, a post he held for 12 years. Dr Tayton-Martin has been COO of Adaptimmune since the company's foundation in 2008, having joined from Adaptimmune's predecessor companies, MediGene and Avidex.